Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Omvik

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Hypertension|May 23, 2002
Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)Eva Gerdts, Hans Bjornstad, Sigurd Toft, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 25, 2004
[Treatment of hypertension in patients with left ventricular hypertrophy]Per Omvik, Bjørn Bratland, Gerhard Gerhardsen, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial populationTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Blood Pressure|October 25, 2006
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)Eva Gerdts, Hans Björnstad, Richard B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2006
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trialEva Gerdts, Kristian Wachtell, Per Omvik, et al.
Journal of Hypertension|March 2, 2011
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudyMichael H Olsen, Kristian Wachtell, Hans Ibsen, et al.
American Journal of Hypertension|June 15, 2012
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE studyAnders M Greve, Michael H Olsen, Jonathan N Bella, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Hypertension|May 23, 2002
Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)Eva Gerdts, Hans Bjornstad, Sigurd Toft, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|March 25, 2004
[Treatment of hypertension in patients with left ventricular hypertrophy]Per Omvik, Bjørn Bratland, Gerhard Gerhardsen, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial populationTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Blood Pressure|October 25, 2006
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)Eva Gerdts, Hans Björnstad, Richard B Devereux, et al.
Hypertension (Dallas, Tex. : 1979)|December 21, 2006
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trialEva Gerdts, Kristian Wachtell, Per Omvik, et al.
Journal of Hypertension|March 2, 2011
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudyMichael H Olsen, Kristian Wachtell, Hans Ibsen, et al.
American Journal of Hypertension|June 15, 2012
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE studyAnders M Greve, Michael H Olsen, Jonathan N Bella, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 4